Stock Detail
ISIS PHARMACEUTICALS INC
Biotechnology
ISIS @ Yahoo Finance | ISIS Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $6.89 | $7.08 | $-0.15 | -2.13% | 0.00 | $7.04 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $6.96 | $6.86 | 457,237 | 686.98M | 704,538.67 | -8.72 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 7.16 | 7.02 | 6.94 | 6.80 | 6.72 |
Stock Profile
Isis Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs to treat various therapeutic areas, including inflammatory, metabolic, and cardiovascular diseases, as well as cancer. The company operates through two segments, Drug Discovery and Development, and Ibis. The Drug Discovery and Development segment develops antisense inhibitors through its proprietary technology. The company markets its antisense drug, Vitravene, for the treatment of cytomegalovirus and retinitis in AIDS patients in the United States and Europe. It also develops new formulations of antisense drugs, such as oral, topical cream, subcutaneous, intravitreal, aerosol, and enema. The company's drugs under development include Alicaforsen for Ulcerative Colitis in Phase II clinical trial and ISIS 113715 for diabetes in Phase II clinical trial. In addition, it develops second-generation inhibitors, such as apoB-100 for the lowering of cholesterol and ISIS 301012, a Phase I study of an oral capsule formulation. The Ibis segment offers Triangulation Identification for Genetic Evaluation of Risks (TIGER) technology, a biosensor system, for identification of infectious diseases. TIGER biosensor system identifies various bacteria and viruses in both environmental and human clinical samples and used for epidemiological surveillance, biological products screening, and microbial forensics applications. The company has strategic alliance and collaboration agreements with Novartis Ophthalmics AG; Ercole Biotech, Inc.; Alnylam Pharmaceuticals, Inc.; OncoGenex Technologies, Inc.; Santaris Pharma A/S; Eli Lilly and Company; Antisense Therapeutics, Ltd.; and Sarissa, Inc. Isis Pharmaceuticals was founded in 1989 and is headquartered in Carlsbad, California.